NeoGenomics, Inc. (NASDAQ:NEO) Shares Acquired by Loomis Sayles & Co. L P

Loomis Sayles & Co. L P increased its stake in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 48.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,791,792 shares of the medical research company’s stock after purchasing an additional 584,502 shares during the quarter. Loomis Sayles & Co. L P’s holdings in NeoGenomics were worth $29,528,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Bellevue Group AG increased its position in shares of NeoGenomics by 34.2% in the 3rd quarter. Bellevue Group AG now owns 1,612,612 shares of the medical research company’s stock valued at $23,786,000 after purchasing an additional 410,516 shares during the last quarter. Jennison Associates LLC increased its holdings in NeoGenomics by 18.7% in the fourth quarter. Jennison Associates LLC now owns 1,514,756 shares of the medical research company’s stock valued at $24,963,000 after buying an additional 238,288 shares during the last quarter. Segall Bryant & Hamill LLC raised its stake in NeoGenomics by 11.6% in the fourth quarter. Segall Bryant & Hamill LLC now owns 2,113,822 shares of the medical research company’s stock valued at $34,836,000 after buying an additional 220,415 shares in the last quarter. Vanguard Group Inc. lifted its holdings in NeoGenomics by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 14,239,887 shares of the medical research company’s stock worth $234,673,000 after buying an additional 195,793 shares during the last quarter. Finally, State Street Corp boosted its position in shares of NeoGenomics by 1.6% during the 3rd quarter. State Street Corp now owns 4,958,582 shares of the medical research company’s stock worth $73,139,000 after acquiring an additional 80,449 shares in the last quarter. Hedge funds and other institutional investors own 98.50% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on NEO shares. Benchmark cut NeoGenomics from a “buy” rating to a “hold” rating in a research note on Monday, January 13th. Piper Sandler cut their price objective on shares of NeoGenomics from $21.00 to $18.00 and set an “overweight” rating on the stock in a report on Wednesday, February 26th. The Goldman Sachs Group lowered their target price on shares of NeoGenomics from $20.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday, January 28th. Needham & Company LLC cut their price target on shares of NeoGenomics from $19.00 to $18.00 and set a “buy” rating on the stock in a research note on Wednesday, February 19th. Finally, Jefferies Financial Group initiated coverage on shares of NeoGenomics in a research report on Tuesday, December 10th. They issued a “buy” rating and a $22.00 price target for the company. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $19.60.

NeoGenomics Stock Performance

NASDAQ NEO opened at $9.48 on Friday. The firm has a market cap of $1.22 billion, a P/E ratio of -15.29 and a beta of 1.28. NeoGenomics, Inc. has a 52-week low of $8.98 and a 52-week high of $19.12. The business’s 50-day moving average price is $12.01 and its 200 day moving average price is $14.40. The company has a quick ratio of 1.91, a current ratio of 1.98 and a debt-to-equity ratio of 0.38.

NeoGenomics (NASDAQ:NEO) last announced its earnings results on Tuesday, February 18th. The medical research company reported ($0.02) earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.05). NeoGenomics had a negative net margin of 11.92% and a negative return on equity of 2.10%. The company had revenue of $172.00 million during the quarter, compared to analysts’ expectations of $173.40 million. On average, equities research analysts expect that NeoGenomics, Inc. will post -0.2 earnings per share for the current year.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.